2.845USD+2.89%Mkt Cap: 260.48M USDP/E: —Last update: 2026-06-01
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody …
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap260.48M USD
Enterprise Value207.61M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-36.12M USD
Revenue/Share—
Last Price2.845 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees15
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.61
PEG—
EV/EBITDA-4.77
EV/Revenue—
P/S—
P/B5.02
EPS (TTM)-0.42
EPS (Forward)-0.43
52W Range
0.490075% of range3.620
52W High3.620 USD
52W Low0.4900 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-59.73%
ROA-52.74%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-26.39M USD
CapEx (TTM)2.03M USD
FCF Margin—
FCF Yield-9.14%
Net Debt-54.25M USD
Net Debt/EBITDA1.25
Balance Sheet
Debt/Equity0.00
Current Ratio8.96
Quick Ratio8.35
Book Value/Sh0.5680 USD
Cash/Share0.5930 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)6.000 USD
Target Range4.000 USD – 8.000 USD
# Analysts7
Ownership
Shares Out.91.88M
Float42.82M
Insiders1.18%
Institutions81.31%
Short Interest
Short Ratio1.1d
Short % Float1.15%
Short % Out.1.00%
Shares Short920.21K
Short (prev mo.)863.74K
Technical
SMA 502.510 (+13.4%)
SMA 2001.726 (+64.9%)
Beta1.57
S&P 52W Chg27.94%
Avg Vol (30d)779.80K
Avg Vol (10d)794.48K
Technical Indicators
RSI (14)59.9
MACD0.0838
MACD Signal0.0098
MACD Hist.+0.0740
BB Upper2.898 USD
BB Middle2.433 USD
BB Lower1.967 USD
BB Width38.31%
ATR (14)0.1880 USD
Vol Ratio (20d)0.42x